NEW YORK (GenomeWeb News) – BG Medicine today priced a public offering of common stock that is anticipated to bring in $8.9 million in net proceeds.

The Waltham, Mass.-based firm plans to offer 6,452,000 shares of its common stock at $1.55 per share. It also has granted the offering's underwriter a 30-day option to purchase up to an additional 967,800 shares to cover any overallotments.

Lazard Capital Markets is the sole book-running manager for the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.